(Q35203402)

7 August 2017

1 reference

title

Simplified regimens for treating HIV infection and AIDS. (English)

1 reference

7 August 2017

Peter J Piliero

1

1 reference

7 August 2017

Joseph P Colagreco

series ordinal

2

1 reference

7 August 2017

publication date

1 July 2003

1 reference

Journal of the American Academy of Nurse Practitioners

7 August 2017

published in

1 reference

7 August 2017

volume

15

1 reference

7 August 2017

issue

7

1 reference

7 August 2017

page(s)

305-312

1 reference

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Factors affecting adherence to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Adherence to HIV combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

The relationship of disease severity, health beliefs and medication adherence among HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Strategies of antiretroviral therapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Adherence to combination antiretroviral therapies in HIV patients of low health literacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Issues in patient compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

Granulocyte-macrophage colony-stimulating factor and fluconazole enhance anti-cryptococcal activity of monocytes from AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB01313.X

10.1111/J.1745-7599.2003.TB01313.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference